MX2019006523A - Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. - Google Patents
Conservacion de respuesta inmunitaria durante regimenes de quimioterapia.Info
- Publication number
- MX2019006523A MX2019006523A MX2019006523A MX2019006523A MX2019006523A MX 2019006523 A MX2019006523 A MX 2019006523A MX 2019006523 A MX2019006523 A MX 2019006523A MX 2019006523 A MX2019006523 A MX 2019006523A MX 2019006523 A MX2019006523 A MX 2019006523A
- Authority
- MX
- Mexico
- Prior art keywords
- short
- conservation
- immune response
- response during
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430302P | 2016-12-05 | 2016-12-05 | |
| US201762479605P | 2017-03-31 | 2017-03-31 | |
| PCT/US2017/064775 WO2018106729A1 (en) | 2016-12-05 | 2017-12-05 | Preservation of immune response during chemotherapy regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006523A true MX2019006523A (es) | 2019-10-15 |
Family
ID=62491342
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006523A MX2019006523A (es) | 2016-12-05 | 2017-12-05 | Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. |
| MX2023006991A MX2023006991A (es) | 2016-12-05 | 2019-06-04 | Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006991A MX2023006991A (es) | 2016-12-05 | 2019-06-04 | Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11529352B2 (https=) |
| EP (1) | EP3548030A4 (https=) |
| JP (4) | JP2019536805A (https=) |
| KR (4) | KR20240023677A (https=) |
| CN (3) | CN117530948A (https=) |
| AU (4) | AU2017372856B9 (https=) |
| BR (1) | BR112019011410A2 (https=) |
| CA (1) | CA3045465A1 (https=) |
| IL (4) | IL303038B2 (https=) |
| MX (2) | MX2019006523A (https=) |
| NZ (1) | NZ753631A (https=) |
| WO (1) | WO2018106729A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2968290T3 (da) * | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| RS61273B1 (sr) | 2014-04-30 | 2021-01-29 | Fujifilm Corp | Lipozomska kompozicija i postupak za njeno dobijanje |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| IL303038B2 (en) | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| FI3603620T3 (fi) | 2017-03-31 | 2025-12-02 | Fujifilm Corp | Liposomikoostumus ja farmaseuttinen koostumus |
| WO2019054865A1 (en) * | 2017-09-14 | 2019-03-21 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T-cell based immunotherapy |
| WO2019108589A1 (en) * | 2017-11-30 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
| MX2020007312A (es) | 2018-01-08 | 2021-01-08 | G1 Therapeutics Inc | Regimenes de dosificacion superior de g1t38. |
| CN112218634A (zh) * | 2018-04-09 | 2021-01-12 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| PL3811931T3 (pl) * | 2018-06-20 | 2024-11-18 | Fujifilm Corporation | Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej |
| ES2984147T3 (es) * | 2018-06-20 | 2024-10-29 | Fujifilm Corp | Medicamento combinado que comprende una composición liposómica de gemcitabina encapsulada y bloqueo de punto de control inmunitario |
| EP3853251A1 (en) * | 2018-09-19 | 2021-07-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
| WO2020071349A1 (ja) | 2018-10-01 | 2020-04-09 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 |
| JP2022506829A (ja) * | 2018-11-09 | 2022-01-17 | ジー１、セラピューティクス、インコーポレイテッド | エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン |
| US20220288067A1 (en) * | 2019-04-24 | 2022-09-15 | The Trustees Of The University Of Pennsylvania | Treatment of cancer with cdk inhibitors |
| CN114269376A (zh) * | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 用抗pd-l1抗体治疗癌症的方法 |
| EP3986410A4 (en) * | 2019-06-18 | 2023-06-28 | G1 Therapeutics, Inc. | Patient selection for enhancement of anti-tumor immunity in cancer patients |
| WO2021097064A1 (en) | 2019-11-12 | 2021-05-20 | Pointcloud Inc. | Dual path light detection and ranging system |
| WO2021110122A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Cdk4/6抑制剂的组合疗法 |
| ES3048084T3 (en) | 2020-05-19 | 2025-12-09 | Pharmacosmos Holding As | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| EP4164653A4 (en) * | 2020-06-15 | 2024-06-19 | G1 Therapeutics, Inc. | MORPHIC FORMS OF TRILACICLIB AND METHODS OF PREPARING THE SAME |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| WO2022087018A1 (en) * | 2020-10-19 | 2022-04-28 | G1 Therapeutics, Inc. | Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer |
| JP2023552440A (ja) * | 2020-12-07 | 2023-12-15 | ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー | アトラクチレノリドｉを用いて癌細胞を免疫攻撃に対して感受性にする方法 |
| CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
| WO2023068220A1 (ja) * | 2021-10-18 | 2023-04-27 | 株式会社Preferred Networks | 予測方法及びバイオマーカー |
| WO2023164649A2 (en) * | 2022-02-25 | 2023-08-31 | Lanier Biotherapeutics, Inc. | Anti-alarmin binding molecules and treatment of pneumonitis |
| WO2024050145A1 (en) * | 2022-09-02 | 2024-03-07 | Rs Oncology, Llc | Thiostrepton dosing regimens |
| WO2024216208A2 (en) * | 2023-04-14 | 2024-10-17 | Concarlo Therapeutics, Inc. | Brk peptides and methods of use |
| WO2024238476A2 (en) * | 2023-05-15 | 2024-11-21 | Cedars-Sinai Medical Center | Y chromosome gene signature as a target for cancer therapy in combination with immunotherapy |
| CN117511855B (zh) * | 2023-11-09 | 2024-11-19 | 南京医科大学 | Epha抑制剂在诱导减数分裂中的应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| CA2645633A1 (en) | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| CA2672518A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Organic compounds and their uses |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| EP2320903B1 (en) | 2008-07-29 | 2017-01-18 | Nerviano Medical Sciences S.r.l. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| JP2012504646A (ja) | 2008-10-01 | 2012-02-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護 |
| CN102231983A (zh) | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护 |
| EP3406260B1 (en) | 2009-05-13 | 2020-09-23 | The University of North Carolina at Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| KR102051881B1 (ko) | 2010-10-25 | 2019-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| CN103635189B (zh) | 2011-07-01 | 2016-05-04 | 诺华股份有限公司 | 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗 |
| AU2013239816B2 (en) | 2012-03-29 | 2017-08-24 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
| EP2841417A1 (en) | 2012-04-26 | 2015-03-04 | Francis Xavier Tavares | Synthesis of lactams |
| DK2968290T3 (da) | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| HK1222766A1 (zh) | 2013-03-15 | 2017-07-14 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
| WO2014144596A2 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient protection of hematopoietic stem and progenitor cells against ionizing radiation |
| HK1215374A1 (zh) | 2013-04-08 | 2016-08-26 | Pharmacyclics Llc | 依鲁替尼联合疗法 |
| CA2917858A1 (en) * | 2013-08-02 | 2015-02-05 | Aduro Biotech Holdings, Europe B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
| US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| WO2015161285A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation |
| JP2017515859A (ja) | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| MX2017007390A (es) * | 2014-12-16 | 2017-11-06 | Bristol Myers Squibb Co | Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales. |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| TW201805000A (zh) | 2016-06-20 | 2018-02-16 | 庫拉腫瘤技術股份有限公司 | 利用erk抑制劑之鱗狀細胞癌之治療 |
| JP7106462B2 (ja) | 2016-07-01 | 2022-07-26 | ジー１ セラピューティクス， インコーポレイテッド | Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成 |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| EP3858835A1 (en) | 2016-07-01 | 2021-08-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| AU2017359333B2 (en) | 2016-11-08 | 2024-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| EP3541389A1 (en) | 2016-11-16 | 2019-09-25 | Pfizer Inc | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
| MA46937A (fr) | 2016-11-30 | 2019-10-09 | Oncotyrol Center For Personalized Cancer Medicine Gmbh | 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones en tant qu'inhibiteurs de kinases dépendantes des cyclines |
| IL303038B2 (en) | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| WO2018156812A1 (en) | 2017-02-22 | 2018-08-30 | G1 Therapeutics, Inc. | Treatment of egfr-driven cancer with fewer side effects |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| KR20190117582A (ko) | 2017-02-10 | 2019-10-16 | 쥐원 쎄라퓨틱스, 인크. | 벤조티오펜 에스트로겐 수용체 조정제 |
| US20200108066A1 (en) | 2017-03-30 | 2020-04-09 | Shorn Goel | Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors |
| FI3645001T3 (fi) | 2017-06-29 | 2024-09-25 | G1 Therapeutics Inc | Git38:n morfisia muotoja ja niiden valmistusmenetelmiä |
| WO2019108589A1 (en) | 2017-11-30 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
| WO2019136244A1 (en) | 2018-01-04 | 2019-07-11 | G1 Therapeutics, Inc. | Heterocyclic compounds for the treatment of abnormal cellular proliferation |
| MX2020007312A (es) | 2018-01-08 | 2021-01-08 | G1 Therapeutics Inc | Regimenes de dosificacion superior de g1t38. |
| CN112218634A (zh) | 2018-04-09 | 2021-01-12 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| RS67557B1 (sr) | 2018-08-24 | 2026-01-30 | Pharmacosmos Holding As | Unapređena sinteza 1,4-diazaspiro[5.5]undekan-3-ona |
| JP2022506829A (ja) | 2018-11-09 | 2022-01-17 | ジー１、セラピューティクス、インコーポレイテッド | エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン |
| EP3986410A4 (en) | 2019-06-18 | 2023-06-28 | G1 Therapeutics, Inc. | Patient selection for enhancement of anti-tumor immunity in cancer patients |
| TW202128174A (zh) | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN118215481A (zh) | 2021-07-01 | 2024-06-18 | 海南先声再明医药股份有限公司 | 晚期和/或转移性Trop-2过表达癌症患者的联合治疗 |
-
2017
- 2017-12-05 IL IL303038A patent/IL303038B2/en unknown
- 2017-12-05 WO PCT/US2017/064775 patent/WO2018106729A1/en not_active Ceased
- 2017-12-05 CN CN202311165935.0A patent/CN117530948A/zh active Pending
- 2017-12-05 CN CN202311165820.1A patent/CN117562905A/zh active Pending
- 2017-12-05 CN CN201780075215.1A patent/CN110035759A/zh active Pending
- 2017-12-05 KR KR1020247004113A patent/KR20240023677A/ko not_active Withdrawn
- 2017-12-05 MX MX2019006523A patent/MX2019006523A/es unknown
- 2017-12-05 EP EP17878506.9A patent/EP3548030A4/en active Pending
- 2017-12-05 AU AU2017372856A patent/AU2017372856B9/en active Active
- 2017-12-05 JP JP2019530011A patent/JP2019536805A/ja active Pending
- 2017-12-05 NZ NZ753631A patent/NZ753631A/en unknown
- 2017-12-05 IL IL317919A patent/IL317919A/en unknown
- 2017-12-05 BR BR112019011410-6A patent/BR112019011410A2/pt not_active Application Discontinuation
- 2017-12-05 KR KR1020247004108A patent/KR20240023676A/ko active Pending
- 2017-12-05 CA CA3045465A patent/CA3045465A1/en active Pending
- 2017-12-05 KR KR1020197019110A patent/KR20190092478A/ko not_active Ceased
- 2017-12-05 IL IL311265A patent/IL311265A/en unknown
- 2017-12-05 KR KR1020247004112A patent/KR20240024296A/ko active Pending
-
2019
- 2019-05-26 IL IL266870A patent/IL266870A/en unknown
- 2019-06-04 MX MX2023006991A patent/MX2023006991A/es unknown
- 2019-06-05 US US16/432,244 patent/US11529352B2/en active Active
-
2022
- 2022-06-03 JP JP2022091214A patent/JP7483791B2/ja active Active
- 2022-12-01 US US18/072,963 patent/US12527798B2/en active Active
-
2023
- 2023-09-04 JP JP2023143202A patent/JP7710496B2/ja active Active
- 2023-12-11 AU AU2023282170A patent/AU2023282170B2/en active Active
- 2023-12-11 AU AU2023282168A patent/AU2023282168B2/en active Active
-
2025
- 2025-07-08 JP JP2025115144A patent/JP2025148426A/ja active Pending
- 2025-10-01 AU AU2025242155A patent/AU2025242155A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019006523A (es) | Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. | |
| MX2022006726A (es) | Combinaciones de inhibidores de punto de regulacion y terapeuticos para tratar el cancer. | |
| MX373231B (es) | Agente anticancerigeno. | |
| MX2020003959A (es) | Metodos terapeuticos relacionados con los inhibidores de hsp90. | |
| BR112017000703A2 (pt) | métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit | |
| JO3589B1 (ar) | مثبطات كيناز البروتين c وطرق استخداماتها | |
| ZA202005388B (en) | Methods of treating ulcerative colitis | |
| MX388735B (es) | Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito. | |
| SG10201809701TA (en) | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent | |
| MX2016001793A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| MX377351B (es) | Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico | |
| EA202191556A1 (ru) | Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек | |
| MX2017012867A (es) | Composiciones terapeuticas y metodos de uso para tratar el cancer. | |
| MX385594B (es) | Administracion y dosificacion de diaminofenotiazinas. | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2020006808A (es) | Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral. | |
| MX390755B (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
| EP4253419A3 (en) | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| AR112405A1 (es) | Tratamiento de cáncer de mama triple negativo o cáncer colorrectal con metástasis hepáticas | |
| MX2018004112A (es) | Terapia de combinacion racional para el tratamiento de cancer. | |
| CL2018001434A1 (es) | Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
| MX2021012931A (es) | Polipeptidos multiespecificos activables y terapeuticos con semivida extendida. | |
| EA202091743A1 (ru) | Вакцинация дендритными клетками параллельно с химиотерапией |